On Friday, 10x Genomics Inc (NASDAQ: TXG) was 6.07% up from the session before settling in for the closing price of $19.29. A 52-week range for TXG has been $6.78 – $20.34.
Annual sales at Healthcare sector company slipped by -36.10% over the past five years. When this article was written, the company’s average yearly earnings per share was at 68.59%. With a float of $112.18 million, this company’s outstanding shares have now reached $116.46 million.
10x Genomics Inc (TXG) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 10x Genomics Inc stocks. The insider ownership of 10x Genomics Inc is 11.46%, while institutional ownership is 96.98%. The most recent insider transaction that took place on Nov 24 ’25, was worth 225,852. In this transaction Chief Financial Officer of this company sold 11,888 shares at a rate of $19.00, taking the stock ownership to the 297,385 shares. Before that another transaction happened on Nov 24 ’25, when Company’s insider sold 8,283 for $19.00, making the entire transaction worth $157,363. This insider now owns 432,605 shares in total.
10x Genomics Inc (TXG) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.14 earnings per share (EPS) during the time that was less than consensus figure (set at -0.11) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.37% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
You can see what 10x Genomics Inc (TXG) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.80. Likewise, its price to free cash flow for the trailing twelve months is 33.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.95 in one year’s time.
